Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

109.19USD
3:43pm GMT
Change (% chg)

$-0.34 (-0.31%)
Prev Close
$109.53
Open
$110.13
Day's High
$110.45
Day's Low
$109.06
Volume
111,872
Avg. Vol
551,379
52-wk High
$140.76
52-wk Low
$102.21

Latest Key Developments (Source: Significant Developments)

Dicerna Pharmaceuticals Inc Says Alexion May Terminate Collaboration Agreement At Any Time Without Cause
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - ALEXION MAY TERMINATE COLLABORATION AGREEMENT AT ANY TIME WITHOUT CAUSE FOLLOWING A 90-DAY NOTICE PERIOD.DICERNA PHARMACEUTICALS-ALEXION COLLABORATION AGREEMENT ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS TO COMPANY OF UP TO $600.0 MILLION.  Full Article

Alexion To Acquire Syntimmune
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION TO ACQUIRE SYNTIMMUNE.ALEXION PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALEXION WILL ACQUIRE SYNTIMMUNE FOR AN UPFRONT PAYMENT OF $400 MILLION.ALEXION PHARMACEUTICALS INC - ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND..ALEXION PHARMACEUTICALS INC - ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND.ALEXION PHARMACEUTICALS INC - DEAL FOR TOTAL VALUE OF UP TO $1.2 BILLION.ALEXION PHARMACEUTICALS INC - ALEXION WILL ACQUIRE SYNTIMMUNE, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT PAYMENTS OF UP TO $800 MILLION.  Full Article

Alexion Submits Application For Priority Review, Approval Of ALXN1210
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION SUBMITS APPLICATION FOR PRIORITY REVIEW AND APPROVAL OF ALXN1210 AS A TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE U.S..ALEXION PHARMACEUTICALS INC - ALXN1210 SUBMISSION IN EUROPEAN UNION ON TRACK FOR MID-YEAR AND IN JAPAN FOR SECOND HALF OF YEAR.ALEXION PHARMACEUTICALS INC - ALXN1210 APPLICATION IS SUPPORTED BY "COMPREHENSIVE" DATA FROM TWO PHASE 3 CLINICAL TRIALS.  Full Article

Alexion Holds 97.7 Percent Of Shares In Wilson Therapeutics
Friday, 25 May 2018 

May 25 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION HOLDS 97.7 PERCENT OF THE SHARES IN WILSON THERAPEUTICS AFTER THE INITIAL ACCEPTANCE PERIOD AND DECLARES THE OFFER UNCONDITIONAL.  Full Article

Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study
Thursday, 26 Apr 2018 

April 26 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY.Q1 NON-GAAP EARNINGS PER SHARE $1.68.Q1 GAAP EARNINGS PER SHARE $1.11.Q1 REVENUE $930.9 MILLION VERSUS I/B/E/S VIEW $923.5 MILLION.Q1 EARNINGS PER SHARE VIEW $1.50 -- THOMSON REUTERS I/B/E/S.REGULATORY SUBMISSIONS FROM ALXN1210 PHASE 3 PNH NAIVE AND SWITCH STUDIES PLANNED IN U.S. AND EU IN MID-2018.ALEXION PHARMACEUTICALS - ALXN1210 WAS GENERALLY WELL TOLERATED IN PHASE 3 SWITCH STUDY WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT FOR SOLIRIS.ALEXION - PHASE 3 SWITCH STUDY SHOWED NON-INFERIORITY OF ALXN1210 TO SOLIRIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAD BEEN STABLE ON SOLIRIS.PHASE 3 SWITCH STUDY ALSO DEMONSTRATED NON-INFERIORITY ON ALL FOUR KEY SECONDARY ENDPOINTS.SEES 2018 TOTAL REVENUES $3,925 TO $3,985 MILLION.SEES 2018 SOLIRIS REVENUES OF $3,380 MILLION TO $3,420 MILLION.SEES 2018 EARNINGS PER SHARE $1.35 TO $1.75.SEES 2018 NON-GAAP EARNINGS PER SHARE $6.75 TO $6.90.FY2018 EARNINGS PER SHARE VIEW $6.86, REVENUE VIEW $3.98 BILLION -- THOMSON REUTERS I/B/E/S.ALEXION - 2018 FINANCIAL GUIDANCE ASSUMES UNFAVORABLE SOLIRIS REVENUE IMPACT OF $90-$110 MILLION FROM ALXN1210 & OTHER CLINICAL TRIAL RECRUITMENT VERSUS PRIOR YEAR.EXPECTS TO INCUR ADDITIONAL RESTRUCTURING AND RELATED EXPENSES OF APPROXIMATELY $15 MILLION TO $80 MILLION IN 2018.  Full Article

Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING.ALEXION PHARMACEUTICALS SAYS CFO PAUL CLANCY'S TOTAL 2017 COMPENSATION WAS $11.4 MILLION - SEC FILING.  Full Article

Alexion reports Q3 non-GAAP earnings per share of $1.44
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alexion Pharmaceuticals Inc :Alexion reports third quarter 2017 results.Q3 non-GAAP earnings per share $1.44.Q3 GAAP earnings per share $0.35.Q3 revenue $859 million versus I/B/E/S view $864.5 million.Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S.Alexion Pharmaceuticals Inc - ‍provides updated 2017 guidance​.Alexion Pharmaceuticals Inc sees ‍ 2017 total revenues $3,475 million to $3,525 million​.Alexion Pharmaceuticals Inc sees ‍ 2017 GAAP earnings per share $2.00 to $2.35​.Alexion Pharmaceuticals Inc sees ‍ 2017 non-GAAP earnings per share $5.50 to $5.65​.Alexion Pharmaceuticals Inc - ‍2017 guidance assumes Soliris revenue impact of $80 million to $90 million from ALXN1210, other clinical trial recruitments.Alexion Pharma - ‍plans to initiate Single, PK-based Phase 3 study of ALXN1210 delivered subcutaneously once/ week to support registration in PNH, aHUS​.FY2017 earnings per share view $5.60 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.52 billion -- Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals says U.S. FDA approves Soliris for treatment of patients with GMG
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::FDA approves soliris® (eculizumab) for the treatment of patients with generalized myasthenia gravis (gmg).  Full Article